Abstract
Background. A 51-year-old man presented with an 8 month history of migratory pain and weakness.
Investigations. Conventional X-ray, MRI, laboratory investigations including serum electropheresis and immunofixation, measurement of the glomerular filtration rate and levels of serum creatinine and lactate dehydrogenase, and 24 h urine analysis for proteinuria.
Diagnosis. Durie–Salmon stage IIIB multiple myeloma with IgG λ gammopathy and renal impairment associated with urinary excretion of free λ light chains.
Management. Initially, the patient received supportive analgesia with metamizol and opioids, erythropoiesis-stimulating agents and monthly administration of bisphosphonates. A standard regimen of bortezomib, doxorubicin and dexamethasone was started, but the patient did not respond and developed severe renal failure. Treatment was switched to low-dose lenalidomide and high-dose dexamethasone. The lenalidomide dose was gradually increased up to 15 mg daily and the dexamethasone dose reduced to 40 mg once a week. Therapy was well tolerated, and the patient underwent autologous stem-cell transplantation around 16 months after start of induction treatment and 12 months after the start of lenalidomide-based therapy. At 2 years after initiation of lenalidomide-based therapy, the patient remains in partial remission with stable renal function and excellent performance status.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
Boyle, P. & Ferlay, J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16, 481–488 (2005).
American Cancer Society. Detailed guide: multiple myeloma. What are the risk factors for multiple myeloma? Cancer Reference Information [online] (2010).
Kristinsson, S. Y. et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Hematologica 94, 1714–1720 (2009).
Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962–2972 (2008).
Dimopoulos, M. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23, 1545–1556 (2009).
Ludwig, H. et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15, 6–25 (2010).
Eriksson, T. et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J. Pharm. Pharmacol. 55, 1701–1706 (2003).
Terpos, E., Roussou, M. & Dimopoulos, M. A. Bortezomib in multiple myeloma. Expert Opin. Drug Metab. Toxicol. 4, 639–654 (2008).
Chen, N. et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol. 47, 1466–1475 (2007).
Oakervee, H. E. et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Hematol. 129, 755–762 (2005).
Sterz, J. et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin. Investig. Drugs 17, 879–895 (2008).
Kastritis, E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Hematologica 9 2, 546–549 (2007).
Ludwig, H. et al. Bortezomib-doxorubicin-dexamethasone (BDD) in patients with acute light chain induced renal failure (ARF) in multiple myeloma (MM). Final results of a phase II study [abstract 3862]. Blood 114, 1486a (2009).
Weber, D. et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function [abstract 3547]. Blood 108, 1012a (2006).
Weber, D. M. et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function [abstract 8542]. J. Clin. Oncol. 26 (Suppl.), 464s (2008).
Reece, D. E. et al. Use of lenalidomide (Revlimid®) ± corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels [abstract 3548]. Blood 108, 1013a (2006).
Weber, D. M. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133–2142 (2007).
Dimopoulos, M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123–2132 (2007).
Niesvizky, R. et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Hematol. 138, 640–643 (2007).
Dimopoulos, M. A., Kastritis, E., Rosinol, L., Bladé, J. & Ludwig, H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22, 1485–1493 (2008).
Palumbo, A. et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev. 23, 87–93 (2009).
Rajkumar, S. V. et al. High-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29–37 (2010).
Rayner, H. C., Haynes, A. P., Thompson, J. R., Russell, N. & Fletcher, J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q. J. Med. 79, 517–525 (1991).
Kumar, S. et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21, 2035–2042 (2007).
Popat, U. et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol. Blood Marrow Transplant. 15, 718–723 (2009).
Kumar, S. et al. International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114, 1729–1735 (2009).
Mark, T. et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol. Blood Marrow Transplant. 14, 795–798 (2008).
Giralt, S. et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2 3, 1904–1912 (2009).
Palumbo, A. et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract 613]. Blood 114, a253 (2009).
Acknowledgements
Written consent for publication was obtained from the patient. Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H. Ludwig declares associations with the following companies: Celgene and Ortho-Biotech. N. Zojer declares no competing interests.
Supplementary information
Supplementary Information
Supplementary Information (DOC 41 kb)
Rights and permissions
About this article
Cite this article
Ludwig, H., Zojer, N. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol 7, 289–294 (2010). https://doi.org/10.1038/nrclinonc.2010.31
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.31
This article is cited by
-
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
Journal of Medical Case Reports (2011)
-
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Leukemia (2011)
-
Lenalidomide for bortezomib-resistant multiple myeloma
Nature Reviews Clinical Oncology (2010)
-
Lenalidomide efficacy in bortezomib-resistant myeloma
Nature Reviews Clinical Oncology (2010)
-
Author reply: Lenalidomide for bortezomib-resistant multiple myeloma
Nature Reviews Clinical Oncology (2010)